These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34465922)

  • 1. Biomarkers show value of studying dementia in Down syndrome.
    Granholm AC; Ledreux A
    Nat Rev Neurol; 2021 Oct; 17(10):599-600. PubMed ID: 34465922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome.
    Rafii MS; Zaman S; Handen BL
    J Prev Alzheimers Dis; 2021; 8(1):48-51. PubMed ID: 33336224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome.
    Wiseman FK; Al-Janabi T; Hardy J; Karmiloff-Smith A; Nizetic D; Tybulewicz VL; Fisher EM; Strydom A
    Nat Rev Neurosci; 2015 Sep; 16(9):564-74. PubMed ID: 26243569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive decline and dementia in Down syndrome.
    Hithersay R; Hamburg S; Knight B; Strydom A
    Curr Opin Psychiatry; 2017 Mar; 30(2):102-107. PubMed ID: 28009725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Alzheimer-type dementia and Down syndrome].
    Johannsen P; Mai J
    Ugeskr Laeger; 1995 Feb; 157(8):1021-4. PubMed ID: 7879299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
    Fagan AM; Henson RL; Li Y; Boerwinkle AH; Xiong C; Bateman RJ; Goate A; Ances BM; Doran E; Christian BT; Lai F; Rosas HD; Schupf N; Krinsky-McHale S; Silverman W; Lee JH; Klunk WE; Handen BL; Allegri RF; Chhatwal JP; Day GS; Graff-Radford NR; Jucker M; Levin J; Martins RN; Masters CL; Mori H; Mummery CJ; Niimi Y; Ringman JM; Salloway S; Schofield PR; Shoji M; Lott IT; ;
    Lancet Neurol; 2021 Aug; 20(8):615-626. PubMed ID: 34302786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Search for Biomarkers of Alzheimer's Disease in Down Syndrome.
    Handen BL
    Am J Intellect Dev Disabil; 2020 Mar; 125(2):97-99. PubMed ID: 32058812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood-based biomarkers for Down syndrome and Alzheimer's disease: A systematic review.
    Petersen ME; O'Bryant SE
    Dev Neurobiol; 2019 Jul; 79(7):699-710. PubMed ID: 31389185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease.
    Sabbagh MN; Fleisher A; Chen K; Rogers J; Berk C; Reiman E; Pontecorvo M; Mintun M; Skovronsky D; Jacobson SA; Sue LI; Liebsack C; Charney AS; Cole L; Belden C; Beach TG
    Arch Neurol; 2011 Nov; 68(11):1461-6. PubMed ID: 22084131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosing Alzheimer Dementia in People with Down Syndrome in Accordance with ICD, DSM V and A/T/N System].
    Nübling G; Wagemann O; Loosli SV; Wlasich E; Danek A; Levin J
    Fortschr Neurol Psychiatr; 2022 Sep; 90(9):416-420. PubMed ID: 35320851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernández S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Alcolea D; Clarimón J; Zaman SH; Blesa R; Lleó A
    Lancet; 2020 Jun; 395(10242):1988-1997. PubMed ID: 32593336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
    Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta-analyses.
    Alhajraf F; Ness D; Hye A; Strydom A
    Dev Neurobiol; 2019 Jul; 79(7):684-698. PubMed ID: 31389176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomal biomarkers in Down syndrome and Alzheimer's disease.
    Hamlett ED; Ledreux A; Potter H; Chial HJ; Patterson D; Espinosa JM; Bettcher BM; Granholm AC
    Free Radic Biol Med; 2018 Jan; 114():110-121. PubMed ID: 28882786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome.
    Schupf N; Patel B; Pang D; Zigman WB; Silverman W; Mehta PD; Mayeux R
    Arch Neurol; 2007 Jul; 64(7):1007-13. PubMed ID: 17620492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome.
    Tatebe H; Kasai T; Ohmichi T; Kishi Y; Kakeya T; Waragai M; Kondo M; Allsop D; Tokuda T
    Mol Neurodegener; 2017 Sep; 12(1):63. PubMed ID: 28866979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebral Amyloid Angiopathy-Related Inflammation in Down Syndrome-Related Alzheimer Disease.
    Aranha MR; Fortea J; Carmona-Iragui M
    Neurology; 2022 Jun; 98(24):1021-1022. PubMed ID: 35470138
    [No Abstract]   [Full Text] [Related]  

  • 18. Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase.
    Mengel D; Liu W; Glynn RJ; Selkoe DJ; Strydom A; Lai F; Rosas HD; Torres A; Patsiogiannis V; Skotko B; Walsh DM
    Alzheimers Res Ther; 2020 Mar; 12(1):27. PubMed ID: 32192521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down syndrome and beta-amyloid deposition.
    Head E; Lott IT
    Curr Opin Neurol; 2004 Apr; 17(2):95-100. PubMed ID: 15021233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome.
    Lleó A; Zetterberg H; Pegueroles J; Karikari TK; Carmona-Iragui M; Ashton NJ; Montal V; Barroeta I; Lantero-Rodríguez J; Videla L; Altuna M; Benejam B; Fernandez S; Valldeneu S; Garzón D; Bejanin A; Iulita MF; Camacho V; Medrano-Martorell S; Belbin O; Clarimon J; Lehmann S; Alcolea D; Blesa R; Blennow K; Fortea J
    Nat Commun; 2021 Jul; 12(1):4304. PubMed ID: 34262030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.